COSCIENS Biopharma Gestione

Gestione criteri di controllo 3/4

COSCIENS Biopharma Il CEO è Gilles Gagnon, nominato in Jun2024, ha un mandato di meno di un anno. possiede direttamente 0.98% delle azioni della società, per un valore di $ 111.60K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 0.4 anni.

Informazioni chiave

Gilles Gagnon

Amministratore delegato

US$133.5k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	1.0%
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Feb 02

AMMINISTRATORE DELEGATO

Gilles Gagnon (70 yo)

less than a year

Mandato

US$133,500

Compensazione

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Director of COSCIENS Biopharma Inc. (formerly known as Aeterna Zentaris Inc.) since June 03, 2024 and had been its Independent Director since January 1, 20...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gilles Gagnon	President	less than a year	US$133.50k	0.98% $ 111.6k
Giuliano La Fratta	Senior VP of Finance & CFO	2.8yrs	US$254.19k	Nessun dato
Michael Teifel	Senior VP of Non-Clinical Development & Chief Scientific Officer	3.5yrs	US$248.24k	Nessun dato
Nicola Ammer	Chief Medical Officer & Senior VP of Clinical Development	6.8yrs	US$212.55k	Nessun dato
Matthias Gerlach	Senior Vice President Manufacturing and Supply Chain & Head of Production	no data	US$263.11k	Nessun dato

3.2yrs

Durata media

Gestione esperta: Il team dirigenziale di CSCI è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gilles Gagnon	President	4.8yrs	US$133.50k	0.98% $ 111.6k
Genevieve Foster	Independent Director	less than a year	Nessun dato	Nessun dato
Gerald Batist	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Hartmut Michel	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Pierre Labbe	Director	less than a year	Nessun dato	Nessun dato
Ronald Miller	Independent Chairman	no data	Nessun dato	Nessun dato
Marcel Verheij	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
René Frydman	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Alan DeCherney	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Klaus H. Diedrich	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Frans M. Debruyne	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ulf Rapp	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato

0.4yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CSCI non è considerato esperto (durata media del mandato 0.4 anni), il che suggerisce un nuovo consiglio.

COSCIENS Biopharma Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Recent updates

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna slips ~10% after announcing date of reverse stock split

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$1.50

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Aeterna Zentaris names Michael Teifel as chief scientific officer

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: US$1.08

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: US$0.69

New 90-day high: US$0.51

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

New 90-day high: US$0.44

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: US$0.33

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low: US$0.38

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media